Dye-loaded fluorescent polymeric nanoparticles working as light-harvesting nano-antenna, which efficiently transfer the excitation energy to acceptor dyes and, therefore, amplifies emission of the latter are provided.

The instant invention provides near-infrared fluorescent biological contrast agents and methods of using them.

The present invention relates to compounds, compositions, and methods are provided for covalently linking a cargo molecule, such as a therapeutic or a diagnostic agent, to a glycan in the Fab region of an antibody. Also provided are methods of modeling and producing antibodies having de novo Fab glycosylation sites. Also provided are antibody carrier conjugates, methods of using the conjugates.

Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.

Described herein are polymeric compounds including an acceptor dye and donor luminophore, a polymer, and optionally a bioconjugate group. A polymeric compound of the present invention may have a structure represented by: A-B-C or C-A-B, wherein A is an acceptor dye; B is a polymer comprising one or more hydrophobic unit(s) and one or more hydrophilic unit(s); and optionally C, wherein C, when present, comprises a bioconjugate group, wherein one or more donor luminophore(s) are each separately attached to a portion of the polymer and/or to a portion of the acceptor dye. Also described herein are compositions comprising the polymeric compounds and methods of preparing and using the same.

Provided is a novel fluorescent probe which can be used in a spray manner, has an outstandingly high sensitivity-specificity with instantaneousness, and enables detection of a brain tumor.

A fluorescent probe for detecting a brain tumor, including a compound of the following formula (I) or a salt thereof:

##STR00001##

wherein P1 represents an arginine residue, a histidine residue or a tyrosine residue, P2 represents a proline residue or a glycine residue, where P1 is linked to an adjacent N atom by forming an amide bond, and P2 is linked to P1 by forming an amide bond; R.sup.1 represents a hydrogen atom, or 1 to 4 identical or different substituents each independently selected from the group consisting of an optionally substituted alkyl group, a carboxyl group, an ester group, an alkoxy group, an amide group and an azide group; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 each independently represent a hydrogen atom, a hydroxyl group, an optionally substituted alkyl group or a halogen atom; R.sup.8 and R.sup.9 each independently represent a hydrogen atom or an alkyl group;

X represents O, Si(R.sup.a)(R.sup.b), Ge(R.sup.a)(R.sup.b), Sn(R.sup.a)(R.sup.b), C(R.sup.a) (R.sup.b) or P(═O)(R.sup.a); R.sup.a and R.sup.b each independently represent a hydrogen atom, an alkyl group or an aryl group; and Y represents a C.sub.1-C.sub.3 alkylene group.

The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject.

The present disclosure provides conjugate structures (e.g., polypeptide conjugates) and hydrazinyl-indole compounds used to produce these conjugates. The disclosure also provides methods of production of such conjugates, as well as methods of using the same.

Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.

An embodiment provides a method for treatment of the COVID-19 virus, including: preparing an intravenous infusion, wherein the intravenous infusion comprises at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; introducing the intravenous infusion to a patient; forming a virion antibody complex, wherein the virion antibody comprises the at least one humanized monoclonal antibody against the SARS-CoV-2 spike protein; and monitoring the virion antibody complex from a sample of a body fluid. Other aspects are described and claimed.